114 related articles for article (PubMed ID: 10456444)
21. Functional characterization of polymorphisms in the human TFPI gene.
Skretting G; Stavik B; Landvik NE; Myklebust CF; Iversen N; Zienolddiny S; Sandset PM
Biochem Biophys Res Commun; 2010 Jun; 397(1):106-11. PubMed ID: 20519147
[TBL] [Abstract][Full Text] [Related]
22. Mutations at the activated protein C cleavage sites Arg336 and Arg562 of factor VIII in Thai patients with venous thrombosis.
Prayoonwiwat W; Arnutti P; Nathalang O; Suwanasophon C; Viputtigul K
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):880-3. PubMed ID: 12041568
[TBL] [Abstract][Full Text] [Related]
23. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis.
Villa P; Aznar J; Vaya A; España F; Ferrando F; Mira Y; Estellés A
Thromb Haemost; 1999 Sep; 82(3):1011-4. PubMed ID: 10494755
[TBL] [Abstract][Full Text] [Related]
24. Protein S is a cofactor for tissue factor pathway inhibitor.
Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM
Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502
[TBL] [Abstract][Full Text] [Related]
25. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[TBL] [Abstract][Full Text] [Related]
26. The paradoxical association between inherited factor VII deficiency and venous thrombosis.
Marty S; Barro C; Chatelain B; Fimbel B; Tribout B; Reynaud J; Schved JF; Giansily-Blaizot M
Haemophilia; 2008 May; 14(3):564-70. PubMed ID: 18282149
[TBL] [Abstract][Full Text] [Related]
27. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
[TBL] [Abstract][Full Text] [Related]
28. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
29. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease.
Guédon C; Le Cam-Duchez V; Lalaude O; Ménard JF; Lerebours E; Borg JY
Am J Gastroenterol; 2001 May; 96(5):1448-54. PubMed ID: 11374681
[TBL] [Abstract][Full Text] [Related]
30. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
31. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
[TBL] [Abstract][Full Text] [Related]
32. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population.
Hoppe B; Tolou F; Dörner T; Kiesewetter H; Salama A
Thromb Haemost; 2006 Oct; 96(4):465-70. PubMed ID: 17003923
[TBL] [Abstract][Full Text] [Related]
33. The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece.
Ioannou HV; Mitsis M; Eleftheriou A; Matsagas M; Nousias V; Rigopoulos C; Vartholomatos G; Kappas AM
Int Angiol; 2000 Dec; 19(4):314-8. PubMed ID: 11305729
[TBL] [Abstract][Full Text] [Related]
34. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
[TBL] [Abstract][Full Text] [Related]
35. Effect of genetic variation in the human S-adenosylhomocysteine hydrolase gene on total homocysteine concentrations and risk of recurrent venous thrombosis.
Gellekink H; den Heijer M; Kluijtmans LA; Blom HJ
Eur J Hum Genet; 2004 Nov; 12(11):942-8. PubMed ID: 15241484
[TBL] [Abstract][Full Text] [Related]
36. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
[TBL] [Abstract][Full Text] [Related]
37. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study.
Almasy L; Soria JM; Souto JC; Warren DM; Buil A; Borrell M; Muñoz X; Sala N; Lathrop M; Fontcuberta J; Blangero J
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1489-92. PubMed ID: 15845911
[TBL] [Abstract][Full Text] [Related]
38. R147W mutation of PROC gene is common in venous thrombotic patients in Taiwanese Chinese.
Tsay W; Shen MC
Am J Hematol; 2004 May; 76(1):8-13. PubMed ID: 15114590
[TBL] [Abstract][Full Text] [Related]
39. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use.
Legnani C; Palareti G; Guazzaloca G; Cosmi B; Lunghi B; Bernardi F; Coccheri S
Eur Heart J; 2002 Jun; 23(12):984-90. PubMed ID: 12069454
[TBL] [Abstract][Full Text] [Related]
40. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria.
Ariëns RA; Moia M; Rivolta E; Ponticelli C; Mannucci PM
Thromb Haemost; 1999 Sep; 82(3):1020-3. PubMed ID: 10494757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
